Mucosal delivery of therapeutic molecules, proteins, or particles coupled to ceramide lipids
AssigneeChildren's Medical Center Corporation
InventorsWayne I. Lencer, Daniel JF Chinnapen, Randy Mrsny
Life of this patent
Estimating the term…
Abstract
Described herein are compositions and methods useful for allowing for the absorption (passage) of agents of interest, such as therapeutic agents, across epithelial and mucosal barriers and/or into certain subcellular compartments of the cell, such as the recycling endosome (RE), Golgi, and the endoplasmic reticulum (ER).
Claims39
A delivery vehicle comprising a glycosphingolipid and an agent to be delivered, wherein the glycosphingolipid comprises a ceramide that comprises (a) a short chain fatty acid (C4-C12) or (b) a long chain fatty acid (C14-C28) comprising at least one cis double bond between two carbon atoms and the agent to be delivered is attached to the oligosaccharide of the glycospingolipid.
2-3. (canceled)
5-7. (canceled)
(canceled)
(canceled)
(canceled)
A glycosphingolipid-therapeutic agent complex comprising a glycosphingolipid attached to a therapeutic agent, wherein the fatty acid of the ceramide comprises (a) 4-12 carbon atoms or (b) 14-28 carbon atoms with at least one cis double bond between two carbon atoms and wherein the therapeutic agent is attached to the oligosaccharide of the glycosphingolipid.
15-16. (canceled)
18-20. (canceled)
(canceled)
24-25. (canceled)
A glycosphingolipid-therapeutic agent complex, wherein the glycosphingolipid comprises a ceramide that comprises (a) a short chain (C4-C12) fatty acid or (b) a long chain (C14-C28) fatty acid comprising a cis double bond and the therapeutic agent is attached to the oligosaccharide of the glycosphingolipid.
27-28. (canceled)
30-32. (canceled)
(canceled)
36-37. (canceled)
A ganglioside-therapeutic agent complex comprising monosialotetrahexosylganglioside (GM1) attached to a therapeutic agent, wherein the fatty acid component of the ceramide comprises (a) 4-12 carbon atoms with no double bonds between carbon atoms or (b) 14-28 carbon atoms comprising at least one cis double bond between two carbon atoms and the therapeutic agent is attached to the oligosaccharide of monosialotetrahexosylganglioside (GM1).
39-43. (canceled)
46-47. (canceled)
49-57. (canceled)
59-60. (canceled)
A method of treating a disease or condition in an individual in need thereof, comprising administering an effective amount of a ganglioside-therapeutic agent complex to the individual, wherein an effective amount is an amount sufficient to ameliorate/reduce the extent to which the disease or condition occurs in the individual.
62-65. (canceled)
(canceled)
Dependencies are inferred from the claim text.